{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093307","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.179134+00:00","generated_at":"2026-05-31T11:30:47.790058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Geron Q2 net loss $67.4M; RYTELO launch underway with ~160 patients treated by July 31","bullets":["Net loss of $67.4M ($0.10 per share) for Q2 2024, compared to $49.2M ($0.09) in Q2 2023.","RYTELO (imetelstat) commercially launched June 27, 2024; estimated ~160 patients treated as of July 31, 2024.","Total product revenue $780k for Q2; net revenue $882k (vs $29k prior year period).","Cash and marketable securities $430.4M as of June 30, 2024; FY2024 operating expenses guided to $270M-$280M.","NCCN Guidelines updated to include RYTELO as Category 1 for second-line and Category 2A for first-line LR-MDS treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093307","json":"https://secwatch.observer/filing/0000950170-24-093307.json","markdown":"https://secwatch.observer/filing/0000950170-24-093307.md","text":"https://secwatch.observer/filing/0000950170-24-093307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017024093307/0000950170-24-093307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017024093307/gern-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:30:47.790058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}